Key issues for a potential human immunodeficiency virus vaccine.

Area of Science:

• Vaccinology
• Public Health
• Infectious Disease Epidemiology

Background:

• A safe, effective, and affordable human immunodeficiency virus (HIV) vaccine is crucial for controlling the global HIV/acquired immunodeficiency syndrome (AIDS) epidemic.
• Anticipated first-generation HIV vaccines may offer only partial efficacy, similar to some existing licensed vaccines for other diseases.
• Despite lower efficacy, partially effective HIV vaccines hold potential for substantial individual and public health benefits.

Purpose of the Study:

• To advise the Centers for Disease Control and Prevention (CDC) on critical issues concerning the licensure and availability of an HIV vaccine in the United States.
• To summarize key discussions from a January 2002 consultation regarding the use of partially effective HIV vaccines in U.S. prevention programs.
• To outline necessary activities for preparing the U.S. for the introduction of an HIV vaccine.

Main Methods:

• Consultation meeting held in January 2002.
• Discussion of critical issues related to HIV vaccine availability.
• Summary of potential use of partially effective vaccines in HIV prevention.

Main Results:

• First-generation HIV vaccines are expected to have low to moderate efficacy.
• Partially effective HIV vaccines can still offer significant public health and individual benefits.
• Critical issues for the CDC regarding HIV vaccine introduction were identified.

Conclusions:

• Partially effective HIV vaccines could be valuable tools for HIV prevention in the United States.
• Proactive planning and preparation are essential for the successful integration of an HIV vaccine into public health programs.
• Further activities are needed to ensure readiness for the eventual availability of an HIV vaccine.